Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) granted stock options to three newly hired employees on October 31, 2025 as inducement awards under Nasdaq Listing Rule 5635(c)(4). An aggregate of 51,825 options were issued with an exercise price of $2.21 per share, equal to the closing price on the grant date.

The options vest over four years (25% at the first anniversary, then quarterly for the remaining 75%), have a 10-year term, and are subject to Akebia’s inducement award program and stock option agreement, and to continued service requirements.

News Market Reaction – AKBA

-1.42%

-1.42% Session close to close

In the Nov 4 session, AKBA declined 1.42%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 51,825 shares of Akebia’s common stock on October 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $2.21 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com

FAQ

What did Akebia (AKBA) announce on November 3, 2025 about inducement grants?

Akebia announced it granted an aggregate of 51,825 stock options to three new employees, dated October 31, 2025, under Nasdaq Rule 5635(c)(4).

What is the exercise price and grant date for the AKBA inducement options?

The options were granted on October 31, 2025 with an exercise price of $2.21 per share, equal to the closing price that day.

How do the Akebia (AKBA) inducement stock options vest and expire?

Options vest over four years (25% at 1 year, remaining 75% quarterly thereafter) and each has a 10-year term, subject to continued service.

Under which Nasdaq rule were the AKBA inducement awards made?

The awards were granted as inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received AKBA inducement option grants and what is the aggregate size?

Three newly hired employees received options totaling 51,825 shares in aggregate.

Are the Akebia inducement options subject to additional terms or agreements?

Yes; each option is subject to Akebia’s inducement award program rules and an individual stock option agreement.